Takeda Pharmaceutical Company has submitted a biologics license application to the FDA for its Crohn's disease and ulcerative colitis treatment vedolizumab, according to a Gastroenterology & Endoscopy News report.
Vedolizumab has been studied in 2,700 patients in nearly 40 different countries. It is designed to treat moderate to severe Crohn's disease and ulcerative colitis.
More Articles on Gastroenterology:
MIT Researchers Develop 3-D Colonoscopy Technique
Florida Medical Association Names Dr. Alan Harmon President
New York Gastroenterology Associates Opens Scarsdale Office